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PV-0087  
Non-publication of Phase-3 clinical trials in radiotherapy 
J. Perez-Alija
1Hospital Plató, Radioterapia y Oncología, Barcelona, Spain 
1, P. Gallego1, A.Pedro1 
 
Purpose or Objective: As of 1 July 2015 The 
ClinicalTrials.gov database was searched for interventional 
phase-3 trials in radiotherapy with a primary completion date 
before 1 January 2013. According to the 2007 Act of the 
FDAAA results of applicable clinical trials are due not later 
than 12 months after the primary completion date. Our 
objective was to determine how many of these trials have 
not been published a deposition of their results within the 
register yet. 
 
Material and Methods: A first study sample consisted of 802 
interventional phase-3 clinical trials with a primary 
completion date before 1 January 2013. We also took a 
sample which was a subset of the former one, taking into 
account only the interventional phase-3 clinical trials with a 
study start as of 1 January 2008; the main reason was to see 
if those trials starting after the 2007 Act publish more results 
within the register as the trials registered before the 2007 
Act was passed. 
 
Results: In our first study sample, a total of 655 trials 
(81.7%) did not deposit a summary result. Clinical Trials 
starting after the 2007 Act was passed did not do any better: 
422 out of 552 (76.4%) haven’t published a deposition of their 
results within the register. We further analyzed our search 
results taking into account the cancer subtype. The 
percentages of unpublished results for our second study 
sample were the following: Gastric (68%), Rectal (64%), 
Bladder (90%), Sarcoma (70%), Linfoma (78%), Esophagus 
(92%), Cervix (80.6%), Astrocitoma (70%), Testicular (100%), 
Skin (89.5%), Eye (47%), Anal (100%), Palliative (75%), 
Glioblastoma (62.5%), Breast (78%), Lung (73.7%), Head&Neck 
(74.6%), Prostate (68. %). 
 
Conclusion: Our results show that most trials do not report 
results, even if they are forced to do so after the 2007 Act. 
This means that a large number of study participants were 
exposed to the risks of trial participation without the 
supposed benefits that sharing and publishing results would 
have for future generations of patients. 
 
PV-0088  
Rapid changes in brain metastasis during radiosurgical 
planning – implications for MRI timing 
A.L. Salkeld
1Crown Princess Mary Cancer Centre Westmead Hospital, 
Radiation Oncology, Westmead, Australia 
1, W. Wang1, N. Nahar1, L. Gomes2, K. Ng2 
2Westmead Hospital, Radiology, Westmead, Australia 
 
Purpose or Objective: The aim of this prospective study was 
to determine any changes in brain metastases or resection 
cavity volumes between the planning MRI and radiosurgical 
(RS) treatment and if these impacted on management or led 
to an alteration of the RS plan. 
 
Material and Methods: 33 patients with 42 metastases and 12 
tumour resection cavities underwent a planning MRI (MRI-1) 
which was fused to the planning CT. GTV (metastasis) or CTV 
(cavity) were contoured from the T1 and T2 post-gadolinium 
MRI. The GTV/CTV had a 2mm circumferential expansion 
creating a PTV with a plan generated. In addition, a 
verification MRI (MRI-2) was performed 24-48 hours prior to 
RS with volumes re-contoured on MRI-2 (verGTV/verPTV). The 
GTV/CTV and PTV volume changes between MRI-1 and MRI-2 
were recorded and the original plan assessed for coverage of 
the verPTV. A change in plan or management based on MRI-2 
was recorded. 
 
Results: Patient and tumour characteristics are shown in 
Table 1. The median time between MRI-1 and MRI-2 was 7 
days with 27 patients (82%) having 14 days or less and 22 
patients (66%) with 7 days or less. Changes in GTV/CTV and 
PTV volumes between MRI-1 and MRI-2 are shown in Figure 1. 
19 (58%) patients required a change in management based on 
changes in lesions on MRI-2 including: re-planning of RS, or a 
change in treatment to whole-brain radiotherapy (WBRT), 
surgery or best supportive care (BSC). Per lesion, 30 out of 54 
lesions (56%) required re-planning based on MRI-2 including 5 
(42%) cavities and 25 (60%) metastases. 2 patients had rapid 
progression with lepto-meningeal disease diagnosed on MRI-2 
and received WBRT. 1 patient (previously received WBRT) 
had a rapid increase in lesion size and number, with an 
additional 9 lesions noted on MRI-2 and received BSC. 
Reasons for re-planning included: increase in volume (27 
lesions) with 25 verGTV lying outside the original PTV and 2 
touching the original PTV; 2 lesions with a reduction in 
verGTV/verPTV volumes, and 3 patients with an increase in 
the number of metastases or leptomeningeal disease on MRI-
2. 
 
Conclusion: This study is the first to demonstrate changes in 
brain metastases volume from planning MRI to RS treatment, 
where changes often occurred with an interval of 7 days or 
less. An MRI performed within 24-48 hours of RS led to re-
planning or a change in management in more than 50% of 
patients. Therefore, even a short interval between planning 
MRI and RS may result in a geographical miss or over 
treatment, emphasising the need for efficient planning 
processes. 
 
PV-0089  
CyberKnife for prostate cancer patients – early results of 
350 patients irradiation 
L. Miszczyk1, A. Namysl-Kaletka
1Maria Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Radiotherapy, Gliwice, Poland 
1, A. Napieralska1, G. 
Wozniak1, M. Stapor-Fudzinska2, G. Glowacki1, K. Grabinska1 
2Maria Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Treatment Planning, Gliwice, Poland 
 
Purpose or Objective: The aim of this study was an 
evaluation of a toxicity and an early effectiveness of prostate 
cancer patients CyberKnife based radioablation.  
 
Material and Methods: 350 PC patients (186 Low Risk, 164 
Intermediate Risk) aged from 53 to 83 (mean 69) irradiated 
with CK every other day (fd 7.25Gy, TD 36.25Gy, OTT 9 
days). Before the treatment start PSA varied from 0.3 to 19.5 
(median 7.5) and T stage from T1c to T2c. Mean prostate 
dimensions were 42.6x37.2x41.1mm. FU ranged to 48 months 
(mean 12). Directly after the treatment, 1, 4, 8 months later 
and the next every 6 months, the percentage of patients with 
Androgen Deprivation Therapy (ADT), GI (gastro-intestinal) 
and GU (genito-urinary) toxicity (acute up to the 4th month 
and the next late) using the EORTC/RTOG scale and PSA 
concentration were checked.  
 
Results: The percentage of patients without ADT increased 
from 42.6% to 100% 32 months later. The maximal percentage 
of acute G3 adverse effects was 0.5% for GI, 0.6% for GU and 
G2 – 1.9% for GI and 6.0% for GU. No G3 late toxicity was 
observed. The maximal percentage of late G2 toxicity was 
0.5% for GI and 3.0% for GU. PSA median decreased from 2.2 
to 0.2 ng/ml during FU. One patient relapsed (18 months 
after RT- next treated with salvage BT) and one developed 
metastasis in lymphatic node (treated next with salvage CK). 
The detailed results are presented in the Table.  
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 RT end 
1 
month 
4 
months 
8 
months 
14 
months 
20 
months 
26 
months 
32 
months 
38 
months 
N of 
observed 
patients 
350 214 255 212 146 91 53 22 7 
No ADT 
[%] 42.6 64.8 72.7 78.1 85.7 84.4 96.2 100 100 
GI 0 [%] 90.3 91.0 93.9 93.3 97.8 96.1 100 100 100 
GI 1 [%] 9.1 6.6 4.9 6.2 2.2 3.9 - - - 
GI 2 [%] 0.6 1.9 0.8 0.5 - - - - - 
GI 3 [%] - 0.5 0.4 - - - - - - 
GU 0 [%] 77.1 70.8 89.4 95.9 87.3 97.4 98.1 95.2 100 
GU 1 [%] 16.3 25.0 8.2 3.6 9.7 2.6 1.9 4.8 - 
GU 2 [%] 6.0 3.8 2.4 0.5 3.0 - - - - 
GU 3 [%] 0.6 0.4 - - - - - - - 
PSA 
range 
[ng/ml] 
0.008-
20.4 
0.003-
16.3 
0.002-
8.2 0.0-6.4 
0.002-
3.5 
0.04-
2.2 0.0-3.3 
0.02-
3.8 
0.003-
0.6 
PSA 
mean 3.7 1.9 1.1 0.7 0.5 0.4 0.4 0.5 0.3 
PSA 
median 2.2 1.0 0.3 0.3 0.2 0.2 0.2 0.1 0.2 
 
Conclusion: The results obtained permit us to form the 
conclusion that CK based radioablation of low and 
intermediate risk PC patients is an effective treatment 
modality enabling OTT shrinkage and giving a very low 
percentage of adverse effects. 
 
PV-0090  
Stereotactic body radiotherapy for localized prostate 
cancer: a 7-year experience 
Y.W. Lin
1Chi Mei Medical Center, Department of Radiation Oncology, 
Tainan City, Taiwan 
1, K.L. Lin2, L.C. Lin1 
2Chi Mei Medical Center, Department of Radiation Onoclogy, 
Tainan City, Taiwan 
 
Purpose or Objective: Recent understanding of radiobiology 
for prostate cancer suggested hypofractionation might 
achieve a higher therapeutic benefit. Stereotactic body 
radiation therapy (SBRT) is able to delivery high dose per 
fraction precisely. SBRT for prostate cancer might escalate 
biological effective doses while without increasing toxicity. 
Here, we reported our 7-year experience of SBRT for 
localized prostate cancer. 
 
Material and Methods: Between November 2008 and Sep 
2013, a total of 135 patients with clinically localized prostate 
were enrolled for analysis. Patients were low-risk (19%), 
intermediate-risk (37%), and high-risk (44%). Low- and 
intermediate-risk patients were treated with SBRT alone 
(37.5Gy in 5 fractions). High-risk patients were treated with 
whole pelvic irradiation (45Gy in 25 fractions) and SBRT boost 
(21Gy in 3 fractions). All of intermediate- and high-risk 
patients received hormone therapy with different duration. 
The toxicities of gastrointestinal (GI) and genitourinary (GU) 
tracts were scored by Common Toxicity Criteria Adverse 
Effect (CTCAE v3.0). Biochemical failure was defined as 
Phoenix definition. 
 
Results: With a median follow-up of 52 months, there were 
seven patients with biochemical failure (one low-risk patient; 
one intermediate patient; five high-risk patients). The 
estimated 50-month biochemical failure-free survival (BFFS) 
was 95.8%, 96.4% and 81.5% for low-, intermediate, and high-
risk patients, respectively. In the high-risk group, there were 
two late biochemical failures around 60 months. In the SBRT 
alone group, acute Grade 3 GU and GI toxicities were seen in 
2.8% and 1.4% of the low/intermediate-risk patients, 
respectively; the incidence rate of late Grade 3 GU and GI 
toxicity were 3.5% and 0%. In the whole pelvic irradiation 
with SBRT boost group, acute Grade 2 GU and GI toxicity 
occurred in 31% and 21% of the high-risk patients, 
respectively; there was no grade 3 or higher late toxicity of 
GU and only one patient experienced grade 3 GI tract. Most 
of acute toxicity effects in the both groups resolved within 
three to six months of treatment completion. 
 
Conclusion: SBRT with or without whole pelvic irradiation for 
localized prostate cancer is feasible with minimal toxicity 
and encouraging biochemical failure-free survival but should 
be aware of late failure in the high-risk group. Use of whole 
pelvic irradiation for high-risk patients was not associated 
with higher GU or GI toxicity. Continued accrual and follow-
up would be necessary to confirm the biochemical control 
rate and the toxicity profiles. 
 
PV-0091  
Early salvage RT for PSA recurrence postprostatectomy 
improves biochemical progression free survival 
A.B. Hopper
1University of California San Diego, Radiation Medicine and 
Applied Sciences, San Diego, USA 
1, A.P.S. Sandhu1, J.P. Einck1 
 
Purpose or Objective: The definition of biochemical 
recurrence following radical prostatectomy for prostate 
cancer remains controversial in the era of ultrasensitive PSA. 
The AUA definition of PSA > 0.2 ng/mL may not be valid when 
PSA can be detected as low as 0.01 ng/mL. Randomized trials 
have shown a benefit in terms of biochemical progression-
free survival (bPFS) and metastasis free survival with 
adjuvant radiation compared to salvage but many patients 
enrolled as adjuvant actually had detectable PSA values. We 
compared patient outcomes with salvage radiotherapy based 
on pretreatment PSA in order to identify whether early 
salvage radiotherapy is more effective than treating later. 
 
Material and Methods: We performed an institutional review 
board-approved retrospective analysis of patients treated at 
our institution with post-prostatectomy image guided 
radiotherapy from 2005 to 2013. Patients with positive lymph 
nodes, those with an undetectable PSA and those with 
metastatic disease were excluded from our analysis. Data 
were abstracted from each patient’s electronic medical 
record including age, pathologic stage, Gleason score, margin 
status, androgen deprivation therapy, treatment to the 
pelvis, dose and PSA values. Patients were either treated 
with intensity modulated radiotherapy (IMRT) or volumetric 
arc therapy (VMAT) using daily image guidance. The use of 
ADT and the treatment of nodes was at the discretion of the 
treating physician. Radiation dose ranged from 6200-7400 
cGy. Post-salvage bRFS was defined as PSA < 0.4 ng/mL. 
Kaplan-Meier survival analysis was used to compare patients 
with a pre-RT PSA value ≤ 0.2 ng/mL to those with a value > 
0.2 ng/mL. Multivariate Cox regression analysis was used to 
evaluate significance of covariates on bPFS. 
 
Results: 196 patients staged N0 or Nx were treated with 
salvage RT after prostatectomy during the study period. 
Median pre-treatment PSA was 0.29 ng/mL; 117 patients had 
a PSA > 0.2 ng/mL and 79 ≤ 0.2 ng/mL. Median follow up 
time was 36 months, determined by the reverse Kaplan-Meier 
method. Overall comparison of the two groups showed that 
patients treated with a PSA < 0.2 ng/mL had significantly 
improved bPFS (p=0.003) and increased 36 month bPFS (76% 
vs 56%, p=0.0074) compared to those treated with higher PSA 
values (Figure 1). In multivariate analysis a pre-RT PSA > 0.2 
and increasing T stage and Gleason score were all 
significantly associated with worsening bPFS while positive 
margins were significant for improved bPFS (Table 1). Other 
covariates including treatment of nodes and use of ADT did 
not significantly influence bPFS following salvage. 
 
 
